Literature DB >> 19761994

The role of multimodality cardiac imaging in the transplanted heart.

Jerry D Estep1, Dipan J Shah, Sherif F Nagueh, John J Mahmarian, Guillermo Torre-Amione, William A Zoghbi.   

Abstract

Heart transplantation (HT) is an established life-saving treatment option for patients with end-stage heart failure. Despite many advances in the field, the development of acute cellular rejection (ACR) and cardiac allograft vasculopathy (CAV) represent significant causes of 1- and 5-year morbidity and mortality, respectively. The search for noninvasive techniques to assess cardiac allograft function and detect treatable ACR and CAV remains a priority objective for heart transplant professionals. In this review we will: 1) highlight the clinical significance of ACR and CAV in adult cardiac transplant recipients and 2) discuss how different noninvasive imaging modalities (echocardiography, cardiac computed tomography, myocardial perfusion imaging, and cardiac magnetic resonance) have been used in the evaluation of these clinical challenges after HT.

Entities:  

Mesh:

Year:  2009        PMID: 19761994     DOI: 10.1016/j.jcmg.2009.06.006

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  13 in total

Review 1.  Transplant allograft vasculopathy: Role of multimodality imaging in surveillance and diagnosis.

Authors:  Gregory A Payne; Fadi G Hage; Deepak Acharya
Journal:  J Nucl Cardiol       Date:  2015-12-28       Impact factor: 5.952

2.  Prevalence of different forms of infarct-atypical late gadolinium enhancement in patients early and late after heart transplantation.

Authors:  M F Braggion-Santos; F Andre; D Lossnitzer; E Hofmann; J Simpfendörfer; A Dösch; H A Katus; H Steen
Journal:  Clin Res Cardiol       Date:  2014-01       Impact factor: 5.460

Review 3.  Cardiovascular magnetic resonance in heart failure.

Authors:  Theodoros D Karamitsos; Stefan Neubauer
Journal:  Curr Cardiol Rep       Date:  2011-06       Impact factor: 2.931

4.  Magnetic resonance assessment of left ventricular diastolic dysfunction for detecting cardiac allograft vasculopathy in recipients of heart transplants.

Authors:  Haruhiko Machida; Shinichi Nunoda; Kiyotaka Okajima; Kazunobu Shitakura; Akihiko Sekikawa; Yutaka Kubo; Kuniaki Otsuka; Masami Hirata; Shinya Kojima; Eiko Ueno
Journal:  Int J Cardiovasc Imaging       Date:  2011-03-26       Impact factor: 2.357

5.  Cellular and Functional Imaging of Cardiac Transplant Rejection.

Authors:  Yijen L Wu; Qing Ye; Chien Ho
Journal:  Curr Cardiovasc Imaging Rep       Date:  2011-02-01

6.  Allograft coronary artery thrombosis: a case report of early cardiac allograft left ventricular myocardial infarction.

Authors:  Sergio A Torres; Omar Cheema; Dipan J Shah; Guillermo Torre-Amione; Jerry D Estep
Journal:  Methodist Debakey Cardiovasc J       Date:  2012-01

Review 7.  Multi-modal imaging of the pediatric heart transplant recipient.

Authors:  Jonathan H Soslow; Margaret M Samyn
Journal:  Transl Pediatr       Date:  2019-10

8.  Quantification of myocardial interstitial fibrosis and extracellular volume for the detection of cardiac allograft vasculopathy.

Authors:  Ruud B van Heeswijk; Jessica A M Bastiaansen; Juan F Iglesias; Sophie Degrauwe; Samuel Rotman; Jean-Luc Barras; Julien Regamey; Nathalie Lauriers; Piergiorgio Tozzi; Jérôme Yerly; Giulia Ginami; Matthias Stuber; Roger Hullin
Journal:  Int J Cardiovasc Imaging       Date:  2019-11-13       Impact factor: 2.357

9.  Echocardiographic Assessment of Right Ventricular Function in Clinically Well Pediatric Heart Transplantation Patients and Comparison With Normal Control Subjects.

Authors:  Brian R White; Hannah Katcoff; Jennifer A Faerber; Kimberly Y Lin; Joseph W Rossano; Laura Mercer-Rosa; Matthew J O'Connor
Journal:  J Am Soc Echocardiogr       Date:  2019-04       Impact factor: 5.251

Review 10.  Non-invasive cardiac allograft rejection surveillance: reliability and clinical value for prevention of heart failure.

Authors:  Michael Dandel; Roland Hetzer
Journal:  Heart Fail Rev       Date:  2020-09-05       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.